Romansive Raises KRW 4B Series A for Science-Based Sleep Solutions

Romansive Secures KRW 4 Billion in Series A Funding

Romansive (로맨시브), a South Korean foodtech company developing science-based sleep solutions, has raised KRW 4 billion in Series A funding. The round was backed by Lotte Ventures and Dongwon (동원), two conglomerates that have previously supported the company. The funding date is October 2, 2026.

What Romansive Does

Founded in 2021 by CEO Soo-hyun Lee, Romansive operates under its flagship brand Cozaa. The company sells sleep-support drinks, jellies, and ampoules that are built on proprietary technology and patents rather than simple ingredient blending. Its core innovation is a lactic-acid-fermented Ziziphus jujuba seed extract, developed in collaboration with researchers at Seoul National University.

The company has completed both preclinical and clinical studies with Seoul National University Bundang Hospital. It holds a top-tier T4 technology-credit rating and five patents, including a US patent.

Market Position and Backing

Romansive is backed by conglomerates Dongwon and Lotte, providing both strategic support and validation. The company is now focused on developing personalized sleep products and expanding overseas. This includes entry into Japanese distribution channels together with Lotte Ventures.

Acquisition Relevance

The Series A funding positions Romansive to scale its science-backed sleep product line and pursue international growth. For acquirers in the foodtech, wellness, or consumer health sectors, Romansive offers a differentiated technology platform with clinical validation, patent protection, and established corporate partnerships. Its ongoing expansion into personalized sleep solutions and overseas markets, particularly Japan, may present strategic opportunities for companies seeking to enter or consolidate in the sleep and wellness space.

Key Facts

• Company: Romansive (로맨시브)
• Founded: 2021
• CEO: Soo-hyun Lee
• Flagship Brand: Cozaa
• Product Categories: Sleep-support drinks, jellies, ampoules
• Core Technology: Lactic-acid-fermented Ziziphus jujuba seed extract
• Research Partners: Seoul National University, Seoul National University Bundang Hospital
• Technology Rating: T4
• Patents: Five, including a US patent
• Funding Stage: Series A
• Amount Raised: KRW 4 billion
• Funding Date: October 2, 2026
• Investors: Lotte Ventures, Dongwon (동원)

Outlook

With fresh capital, Romansive is expected to advance its personalized sleep product development and accelerate its overseas expansion, including entry into Japanese distribution channels alongside Lotte Ventures. The company's science-first approach and strong patent portfolio may make it an attractive target for acquisition or partnership in the growing sleep economy.